Diane V. Havlir
University of California
San Francisco
995 Potrero Ave.
Bldg. 80
USA
Name/email consistency: high
- Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. Havlir, D.V., Kendall, M.A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S.S., Luetkemeyer, A.F., Hogg, E., Rooney, J.F., Wu, X., Hosseinipour, M.C., Lalloo, U., Veloso, V.G., Some, F.F., Kumarasamy, N., Padayatchi, N., Santos, B.R., Reid, S., Hakim, J., Mohapi, L., Mugyenyi, P., Sanchez, J., Lama, J.R., Pape, J.W., Sanchez, A., Asmelash, A., Moko, E., Sawe, F., Andersen, J., Sanne, I. N. Engl. J. Med. (2011)
- Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. Havlir, D.V., Getahun, H., Sanne, I., Nunn, P. JAMA (2008)
- Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. Havlir, D.V., Koelsch, K.K., Strain, M.C., Margot, N., Lu, B., Ignacio, C.C., Miller, M.D., Wong, J.K. J. Infect. Dis. (2005)
- Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. Havlir, D.V., Strain, M.C., Clerici, M., Ignacio, C., Trabattoni, D., Ferrante, P., Wong, J.K. J. Virol. (2003)
